# A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection

> **NCT05763576** · PHASE1 · TERMINATED · sponsor: **Hoffmann-La Roche** · enrollment: 60 (actual)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** RO7565020
- **OTHER:** Placebo
- **DRUG:** Nucleos(t)ide analogue (NUC) treatment

## Key facts

- **NCT ID:** NCT05763576
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-04-28
- **Primary completion:** 2024-12-23
- **Final completion:** 2024-12-23
- **Target enrollment:** 60 (ACTUAL)
- **Why stopped:** The Sponsor decided to discontinue the development of RO7565020 and as a result the BP44118 study was terminated.
- **Last updated:** 2026-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05763576

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05763576, "A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection". Retrieved via AI Analytics 2026-09-16 from https://api.ai-analytics.org/clinical/NCT05763576. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*